Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 02, 2015 07:30 ET | Source: Bioblast Pharma Ltd.

Bio Blast Announces Key Leadership Changes

TEL AVIV, Israel, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and...
January 08, 2015 07:00 ET | Source: Bioblast Pharma Ltd.

Bio Blast Provides Update on Clinical Trial of Cabaletta(TM) for Occulopharyngeal Muscular Dystrophy (OPMD)

TEL AVIV, Israel, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and...
December 17, 2014 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Receives Notice of Patent Issuance From USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia

TEL AVIV, Israel, Dec. 17, 2014 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd, (Nasdaq:ORPN) a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with...
December 02, 2014 08:00 ET | Source: Bioblast Pharma Ltd.

Bio Blast Pharma to Present Corporate Overview at the Oppenheimer & Co. 25th Annual Healthcare Conference

TEL AVIV, Israel, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with...
November 21, 2014 08:00 ET | Source: Bioblast Pharma Ltd.

Bio Blast Pharma Reports Third Quarter Financial Results

TEL AVIV, Israel, Nov. 21, 2014 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients...
November 19, 2014 09:00 ET | Source: Bioblast Pharma Ltd.

Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3

TEL AVIV, Nov. 19, 2014 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare...
September 22, 2014 08:00 ET | Source: Bioblast Pharma Ltd.

Bio Blast Pharma Announces Initiation of Its Canadian OPMD Clinical Study Center at McGill University, Montreal

TEL AVIV, Israel, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients...
September 17, 2014 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD

Interim Data on First 11 Patients in the Ongoing Phase 2/3 HOPEMD Study Suggest Cabaletta to be Safe and Well Tolerated with No Drug Related Adverse Events TEL AVIV, Israel, Sept. 17, 2014...
September 08, 2014 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast to Ring the NASDAQ Stock Market Opening Bell

TEL AVIV, Israel, Sept. 8, 2014 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd, (Nasdaq:ORPN) a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with...
August 29, 2014 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Reports Second Quarter Financial Results

TEL AVIV, Israel, Aug. 29, 2014 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with...